Health state utilities associated with adult attention-deficit/hyperactivity disorder

被引:6
|
作者
Matza, Louis S. [1 ]
Devine, Mary K. [1 ]
Haynes, Virginia Sutton [2 ]
Davies, Evan W. [3 ]
Kostelec, Jacqueline M. [1 ]
Televantou, Foula [4 ]
Jordan, Jessica B. [1 ]
机构
[1] Evidera, Outcomes Res, Bethesda, MD 20814 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Evidera, Outcomes Res, London, England
[4] Eli Lilly & Co, Windlesham, Surrey, England
来源
PATIENT PREFERENCE AND ADHERENCE | 2014年 / 8卷
关键词
adult ADHD; utility; time trade-off; QUALITY-OF-LIFE; DEFICIT HYPERACTIVITY DISORDER; RELEASE OROS METHYLPHENIDATE; PLACEBO-CONTROLLED TRIAL; LONG-TERM EFFICACY; DOUBLE-BLIND; SKELETAL METASTASES; SOLID TUMORS; ADHD; DIAGNOSIS;
D O I
10.2147/PPA.S62776
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: With growing awareness of the importance of adult attention-deficit/hyperactivity disorder (ADHD) treatment, cost-effectiveness analyses, including utilities, are needed to compare the value of treatment options. Although utilities have been reported for childhood ADHD, little is known about utilities representing adult ADHD. Therefore, the purpose of this study was to estimate utilities associated with adult ADHD. Methods: Health-state descriptions of adult ADHD were drafted based on literature review, interviews with four clinicians, and clinical trial data. Health states were revised based on a pilot study with 26 participants. Final health states were rated in time trade-off interviews with general population respondents in London and Edinburgh, UK. Results: A total of 158 participants completed interviews (mean age=47.0 years; 49.4% female; Edinburgh=80 participants). Mean (standard deviation [SD]) utilities were 0.82 (0.17), 0.68 (0.28), and 0.67 (0.28) for health states describing treatment responders (health state A), nonresponders (health state B), and untreated patients (health state C), respectively. Most participants rated health state A as preferable to B (n=92; 58.2%) and C (n=97; 61.4%). The majority rated B and C as equal (n=125; 79.1%). Paired Student's t-tests found that Lambda had a significantly greater mean utility than B (t=10.0; P<0.0001) and C (t=10.2; P<0.0001). Conclusion: The current study provides utilities that may be used in cost-utility models of treatment for adult ADHD. Results reflected clear differences between health states representing treatment responders and nonresponders/untreated patients. Current utilities were comparable to those previously reported for childhood ADHD.
引用
收藏
页码:997 / 1006
页数:10
相关论文
共 50 条
  • [1] Estimation of Utilities in Attention-Deficit Hyperactivity Disorder for Economic Evaluations
    Lloyd, Andrew
    Hodgkins, Paul
    Sasane, Rahul
    Akehurst, Ron
    Sonuga-Barke, Edmund J. S.
    Fitzgerald, Patrick
    Nixon, Annabel
    Erder, Haim
    Brazier, John
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2011, 4 (04) : 247 - 257
  • [2] Updates in Pharmacologic Strategies in Adult Attention-Deficit/Hyperactivity Disorder
    Anbarasan, Deepti
    Safyer, Gabriella
    Adler, Lenard A.
    CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA, 2022, 31 (03) : 553 - 568
  • [3] Is Adult Attention-Deficit Hyperactivity Disorder Being Overdiagnosed?
    Paris, Joel
    Bhat, Venkat
    Thombs, Brett
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2015, 60 (07): : 324 - 328
  • [4] Attention-Deficit/Hyperactivity Disorder
    Banaschewski, Tobias
    Becker, Katja
    Doepfner, Manfred
    Holtmann, Martin
    Roesler, Michael
    Romanos, Marcel
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2017, 114 (09): : 149 - +
  • [5] Attention-deficit/hyperactivity disorder
    Faraone, Stephen V.
    Bellgrove, Mark A.
    Brikell, Isabell
    Cortese, Samuele
    Hartman, Catharina A.
    Hollis, Chris
    Newcorn, Jeffrey H.
    Philipsen, Alexandra
    Polanczyk, Guilherme V.
    Rubia, Katya
    Sibley, Margaret H.
    Buitelaar, Jan K.
    NATURE REVIEWS DISEASE PRIMERS, 2024, 10 (01)
  • [6] Identification of factors associated with the efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder
    Nagai, Tsutomu
    Kurihara, Tatsuya
    Koya, Hiroaki
    Nakano, Yukako
    Sugisawa, Satoru
    Sambe, Takehiko
    Kishimoto, Keiko
    Kogo, Mari
    Ota, Haruhisa
    Iwanami, Akira
    Uchida, Naoki
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2022, 42 (03) : 249 - 255
  • [7] Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report
    Louis S. Matza
    Kristina Secnik
    Anne M. Rentz
    Sally Mannix
    F. Randy Sallee
    Donald Gilbert
    Dennis A. Revicki
    Quality of Life Research, 2005, 14 (3) : 735 - 747
  • [8] Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report
    Matza, LS
    Secnik, K
    Rentz, AM
    Mannix, S
    Sallee, FR
    Gilbert, D
    Revicki, DA
    QUALITY OF LIFE RESEARCH, 2005, 14 (03) : 735 - 747
  • [9] Pharmacotherapy of Pediatric Attention-Deficit/Hyperactivity Disorder
    Vaughan, Brigette
    Kratochvil, Christopher J.
    CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA, 2012, 21 (04) : 941 - +
  • [10] The Role of Psychologists in Adult Attention-Deficit/Hyperactivity Disorder Testing
    Linck, John F.
    Ostermeyer, Britta
    Valles, Nizete-Ly
    Flores, Araceli
    Shah, Asim A.
    PSYCHIATRIC ANNALS, 2017, 47 (06) : 296 - 302